Citrin deficiency: Does the reactivation of liver aralar-1 come into play and promote HCC development?


Journal

Biochimie
ISSN: 1638-6183
Titre abrégé: Biochimie
Pays: France
ID NLM: 1264604

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 04 05 2021
revised: 25 06 2021
accepted: 30 06 2021
pubmed: 7 7 2021
medline: 8 2 2022
entrez: 6 7 2021
Statut: ppublish

Résumé

Hepatocellular carcinoma (HCC) is a longstanding issue in clinical practice and metabolic research. New clues in better understanding the pathogenesis of HCC might relate to the metabolic context in patients with citrin (aspartate-glutamate carrier 1) deficiency (CD). Because citrin-deficient liver (CDL) is subject to HCC, it represents a unique metabolic model to highlight the mechanisms of HCC promotion, offering different angles of study than the classical metabolic syndrome/obesity/non-alcoholic fatty liver disease (NAFLD)/HCC study axis. In turn, the metabolic features of HCC could shed light on the pathogenesis of CDL. Among these, HCC-induced re-activation of aralar-1 (aspartate-glutamate carrier 2), physiologically not expressed in the adult liver, might take place in CDL, so gene redundancy for mitochondrial aspartate-glutamate carriers would be exploited by the CDL. This proposed (aralar-1 re-activation) and known (citrate/malate cycle) adaptive mechanisms may substitute for the impaired function in CD and are consistent with the clinical remission stage of CD and CD improvement by medium-chain triglycerides (MCT). However, these metabolic adaptive benefits could also promote HCC development. In CD, as a result of PPARα down-regulation, liver mitochondrial fatty acid-derived acetyl-CoA would, like glucose-derived acetyl-CoA, be used for lipid anabolism and fuel nuclear acetylation events which might trigger aralar-1 re-activation as seen in non-CD HCC. A brief account of these metabolic events which might lead to aralar-1 re-activation in CDL is here given. Consistency of this account for CDL events further relies on the protective roles of PPARα and inhibition of mitochondrial and plasma membrane citrate transporters in non-CD HCC.

Identifiants

pubmed: 34228977
pii: S0300-9084(21)00172-3
doi: 10.1016/j.biochi.2021.06.018
pii:
doi:

Substances chimiques

Amino Acid Transport Systems, Acidic 0
Antiporters 0
Calcium-Binding Proteins 0
Mitochondrial Membrane Transport Proteins 0
Organic Anion Transporters 0
SLC25A12 protein, human 0
Triglycerides 0
aspartate-glutamate carrier 0
NAD 0U46U6E8UK
citrin 1340-08-5
Acetyl Coenzyme A 72-89-9

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

20-23

Informations de copyright

Copyright © 2021 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Karine Mention (K)

Univ. Lille, RADEME - Maladies RAres Du Développement et Du Métabolisme: Du Phénotype au Génotype et à La Fonction, Lille, EA, 7364, France; Medical Reference Center for Inherited Metabolic Diseases, Jeanne de Flandre Hospital, CHRU, Lille, France.

Marie Joncquel Chevalier Curt (M)

CHU Lille, Centre de Biologie Pathologie Génétique, UF Métabolisme Général et Maladies Rares, F-59000, Lille, France.

Anne-Frédérique Dessein (AF)

CHU Lille, Centre de Biologie Pathologie Génétique, UF Métabolisme Général et Maladies Rares, F-59000, Lille, France.

Claire Douillard (C)

Endocrinology-Diabetology-Metabolism Department and Medical Reference Center for Inherited Metabolic Diseases Jeanne de Flandre Hospital, CHRU Lille, Lille, France.

Dries Dobbelaere (D)

Univ. Lille, RADEME - Maladies RAres Du Développement et Du Métabolisme: Du Phénotype au Génotype et à La Fonction, Lille, EA, 7364, France; Medical Reference Center for Inherited Metabolic Diseases, Jeanne de Flandre Hospital, CHRU, Lille, France.

Joseph Vamecq (J)

Inserm, Univ. Lille EA 7364 RADEME, CHU Lille, Centre de Biologie Pathologie Génétique, UF Métabolisme Général et Maladies Rares, F-59000, Lille, France. Electronic address: joseph.vamecq@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH